Management of Pyrexia Associated with the Combination of Dabrafenib and Trametinib: Canadian Consensus Statements

Management of Pyrexia Associated with the Combination of Dabrafenib and Trametinib: Canadian Consensus Statements

The combination of dabrafenib and trametinib is a well-established treatment for BRAF-mutated melanoma. However, the effectiveness of this approach may be hindered by the development of treatment-related pyrexia syndrome, which occurs in at least 50% of treated patients. Without appropriate interven...

Full description

Bibliographic Details
Main Authors: Alia Thawer, Wilson H. Miller, Nancy Gregorio, Joël Claveau, Sudha Rajagopal, Kerry J. Savage, Xinni Song, Teresa M. Petrella, on behalf of the Canadian Working Group
Format: Article
Language:English
Published: MDPI AG 2021-09-01
Series:Current Oncology
Subjects:
melanoma
pyrexia
dabrafenib
trametinib
Online Access:https://www.mdpi.com/1718-7729/28/5/304

Internet

https://www.mdpi.com/1718-7729/28/5/304

Similar Items